Endo Names Blaise Coleman Successor to Retiring CEO Paul Campanelli

Endo International’s search for retiring CEO Paul Campanelli’s successor is ending close to home. Dublin, Ireland-based Endo (NASDAQ: [[ticker:ENDP]]) announced Wednesday that Chief Financial Officer Blaise Coleman will become president and CEO starting March 6. He will also take a seat on Endo’s board of directors. Before joining Endo in 2015, Coleman held leadership roles at AstraZeneca (NYSE: [[ticker:AZN]]) and Johnson & Johnson (NYSE: [[ticker:JNJ]]).

Campanelli announced his retirement plans last November. After he steps down from his executive role, he will continue to serve as chairman of the board. To take Coleman’s place, Endo has appointed Mark Bradley to serve as CFO. Bradley is currently Endo’s senior vice president, corporate development, and treasurer.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan